Successful treatment of refractory livedoid vasculitis with rituximab and cyclophosphamide.
- Author:
Eun Joo SONG
1
;
Jong Wan KANG
;
Ji Hun KIM
;
Jin Young KANG
;
Eon Jeong NAM
;
Young Mo KANG
Author Information
1. Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea. ymkang@knu.ac.kr
- Publication Type:Case Report
- Keywords:
Livedoid vasculitis;
Rituximab;
Cyclophosphamide
- MeSH:
Adrenal Cortex Hormones;
Alprostadil;
Antibodies, Monoclonal, Murine-Derived;
Anticoagulants;
Azathioprine;
Cicatrix;
Cyclophosphamide;
Cyclosporine;
Humans;
Immunosuppressive Agents;
Methotrexate;
Mycophenolic Acid;
Platelet Aggregation Inhibitors;
Ulcer;
Vasculitis;
Rituximab
- From:Korean Journal of Medicine
2010;78(4):527-530
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Livedoid vasculitis (LV) is a chronic recurrent cutaneous disease that is characterized by a netlike vascular pattern of purpuric lesions that progress to ulcers and atrophic white scars. The etiology of LV is unknown. Various therapies have been used for LV with inconsistent results, including antiplatelet agents, fibrinolytics, anticoagulants, prostaglandin E1, and immunosuppressive agents, such as systemic corticosteroids, azathioprine, methotrexate, cyclosporine, and mycophenolate mofetil. We present a patient with idiopathic LV refractory to immunosuppressive therapy who had a good response to treatment with rituximab and cyclophosphamide.
